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g-Aminobutyric acid type A (GABAA) receptors, ligand-gated
ion channel receptors for the inhibitory neurotransmitter
GABA, mediate neuronal inhibition in the CNS, including the
spinal cord. Based on their subunit compositions (more spe-
cifically the a subunit isoform included in the pentameric re-
ceptor complex), they can be subdivided into six major
subtypes (from a1 to a6). GABAA receptors containing a1, a2,
a3, or a5 subunits are sensitive to modulation by classical
benzodiazepines, whereas those containing a4 or a6 subunits
instead of a1, a2, a3, or a5 subunits are insensitive. The com-
pound PF-06372865, the subject of a study by Nickolls and
colleagues1 in a recent issue of the British Journal of Anaesthesia,
was developed by Pfizer Inc (Cambridge, UK) as a partial
agonist at the benzodiazepine binding sites of receptors con-
taining a2, a3, or a5 subunits.1 It is mainly this lack of activity
at a1 GABAA receptors that distinguishes PF-06372865 from
classical benzodiazepines. Why is this important, and why
should avoiding activity at a1 GABAA receptors convey anal-
gesic efficacy to benzodiazepine site ligands?
Let us first consider the neurophysiological basis of
GABAergic analgesia. This concept is rooted in the gate control
theory of pain, in which Melzack and Wall2 proposed that
inhibitory (mainly GABAergic) neurones of the spinal dorsal
horn gate incoming nociceptive input and prevent the acti-
vation of ‘pain’ signalling projections by non-painful sensory
input. A large body of evidence indicates that the efficacy of
this inhibitory control is compromised in chronic pain states
through several mechanisms.3 Accordingly, drugs that facili-
tate GABAergic inhibition should in principle be able to correct
this deficit. Indeed, local spinal administration of drugs that
enhance synaptic inhibition reverse heightened pathological
pain sensitivity.4,5 Work in mice expressing genetically engi-
neered GABAA receptor a subunits has shown that a2 (and a3)
GABAA receptors are the most relevant GABAA receptor sub-
types for spinal analgesia, and that a1 and a5 receptors
contribute either nothing (a1) or very little (a5) to this pro-
cess.5,6 This profile fits well with the enriched expression of a2
and a3 GABAA receptors within the spinal dorsal horn,
particularly the superficial layers where incoming nociceptive
fibres terminate.7 The dispensability of a1 GABAA receptors for
analgesia was a crucial finding, as receptors of this subtype
cause the great majority of the unwanted effects of classical
benzodiazepine agonists including sedation, memory impair-
ment, tolerance (loss of efficacy during chronic treatment),
and addiction8 (Fig. 1). This segregation provides a hint as to
why sparing activity at a1 receptors would confer analgesic
activity.
The clinically tolerated doses of benzodiazepines (for in-
dications other than anaesthesia) are limited by undesired
sedation. In fact, typical clinically used doses of classical ben-
zodiazepines yield receptor occupancies <30%.9e12 Preclinical
work has shown that this is too low to yield significant relevant
analgesia, explaining why classical non-selective benzodiaze-
pines are basically devoid of analgesic efficacy. Only when ac-
tivity at a1 GABAA receptors is sufficiently reduced can the
higher doses needed for analgesic efficacy be reached without
putting a patient (or an animal) to sleep (see the work of
Zeilhofer and colleagues13). Inspired by these results, several
groups have tested subtype-selective benzodiazepine site ago-
nists in various rodent pain models. Originally, these
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compounds were developed by groups working in pharma
companies, and in academia in the quest for non-sedative an-
xiolytics. The major outcome of these studies was that such
compounds reverse pathological hyperalgesia in most neuro-
pathic and inflammatory painmodels and also in postoperative
pain, provided that the compounds possessed sufficiently high
modulatory activity and were used at sufficiently high doses.
Such antihyperalgesic activity does not occur with classical
(non-selective) benzodiazepines given systemically. In light of
these encouraging preclinical data, scientists have eagerly
awaited clinical studies.
The first clinical study of potential analgesic actions of a
subtype-selective benzodiazepine site ligand (PF-06372865, the
same compound studied by Nickolls and colleagues1) did not
assess efficacy in experimental human pain, as expected, but
rather was a phase II clinical trial in patients with chronic low
back pain.14 This trial yielded clearly negative results. We
speculated15 about the possible reason(s) for this failure such
as species differences in target receptor expression and func-
tion between rodents and humans, the low predictive value of
preclinical read-outs (both very fashionable critiques nowa-
days), an inappropriate patient population (patients with a
neuropathic pain component were actually excluded), and
insufficient drug dosing.
The new study provides new insights and helps to further
narrow the reasons of the failed low back pain trial. PF-
06372865 was tested in a battery of experimental pain
models in healthy volunteers, and its efficacy was compared
with that of pregabalin, the current gold standard in neuro-
pathic pain treatment. PF-06372865 proved efficacious in
several models with effect sizes comparable with those of
pregabalin. Notably, these positive results suggest that selec-
tive a2 and a3 GABAA receptor modulators exert analgesia not
only in rodents but also in man, thereby largely ruling out
species differences or low predictive values of read-outs in
rodent experiments as underlying causes of the failure in the
low back pain trial. Instead, the new study supports that
insufficient drug dosing was the main problem in the low back
pain trial. Nickolls and colleagues1 tested single doses of 15
and 65mg that led to estimated receptor occupancy of 50% and
80%, respectively, whereas the low back pain trial used smaller
doses of 2.5 and 7.5 mg given twice per day, with estimated
peak steady-state a2 GABAA receptor occupancies of 30% and
50%.14 Preclinical studies in mice indicated that ~70% of a2
GABAA receptors need to be drug-bound (even when a high
intrinsic activity ligand is used) to achieve a significant
reduction in pain thresholds.6 Therefore, the new study sup-
ports a lack of sufficient drug dosing as the most probable
reason for failure of PF-06372865 in the low back pain trial.
This is further supported by another recently published clin-
ical trial on PF-06372865 that used the same dose regimens as
the low back pain trial and failed to demonstrate efficacy
against generalised anxiety disorders.16
Although the results of Nickolls and colleagues1 generally
support previous preclinical findings in mouse pain models,
there are also interesting discrepancies. The most obvious in
our opinion is that PF-06372865 showed efficacy against acute
nociceptive pain, specifically in the mechanical pressure pain,
cold pressor pain, and electrically evoked pain tests in
humans. No significant efficacy was detected in acute models
of hyperalgesia (the sunburn model) and against heat-evoked
pain. PF-06372865 was therefore mostly effective against pain
modalities that appeared resistant to GABAA receptor modu-
lation in mouse experiments.17 The reasons for these differ-
ences are not entirely clear. However, it is tempting to
speculate that differences in the read-out measures are rele-
vant. In the human study, PF-06372865 mainly affected pain
tolerance thresholds but less so pain detection thresholds, which
were the main readouts in the mouse pain models. Taking
these differences into account, the study results are consistent
Fig 1. (a) Chemical structure of PF-06372865, a subtype-selective partial agonist at the benzodiazepine-binding site of a2, a3, and a5 g-
aminobutyric acid A (GABAA) receptors. The inset illustrates chloride currents through GABAA receptor channels recorded in the absence
(control) and presence of a benzodiazepine (BDZ). (b) Schematic illustration and subunit composition of heteropentameric GABAA receptors.
(c) Comparison of the subtype-selectivity of PF-06372865 (blue) with the contribution of the different GABAA receptor subtypes to desired
(green) and undesired (red) in vivo actions of benzodiazepines.
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withwhat could have been predicted from previous preclinical
experiments.
Although the new study is far from providing a definitive
answer to the ongoing question of translatability in drug
research and development, this was never its intended pur-
pose. Importantly, it puts the previous negative result of the
low back pain trial into perspective. If insufficient drug dosing
was the reason for the failure of the low back pain trial, the
good news is that clinical studies published so far have re-
ported excellent tolerability1,14,16 and suggest that there is
significant space for dose augmentation before unwanted ef-
fects become dose limiting.
In the film Back to the Future, the main character Marty
McFly successfully returns home from accidentally being sent
30 yr into the past to find his family in much better circum-
stances than before he left. This concept, rooted in science
fiction, holds some allure in the real-life world of drug research
and development. If only we could go back in time and tweak
our experimental designs. The film ends with their car con-
verted into a hovercraft flying at the camera and the words ‘To
be continued…’ flashing on the screen. We hope that this is
also the case for drugs targeting specific GABAA receptor
subtypes in chronic pain.
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